Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2017

View Archived Issues

Maverick and Takeda announce 5-year collaboration

University of Connecticut and CaroGen collaborate on colon cancer vaccine

PIQUR Therapeutics and Pierre Fabre enter dermato-oncology collaboration

First patient randomized in anaGO study of anakinra for gout

Vertex licenses oncology programs to Merck KGaA

Affimed provides update on NK-cell engager platform

First-in-human study explores use of NP-137 for advanced solid tumors

Celgene initiates phase I trial of CC-90006 in healthy subjects

Initiation of phase I trial assessing single and multiple doses of RTA-901 in healthy adults

Sunovion reports topline data from trials of dasotraline for ADHD and binge-eating disorder

ObsEva completes phase I trial of OBE-022 for treatment of preterm labor

FDA extends NDA review period for baricitinib

Ironwood reviews pipeline at J.P. Morgan conference

Kite Pharma -- finding a cure for cancer using the immune system

Hutchison China MediTech advances pipeline in China with new studies

Kitov Pharmaceuticals Holdings acquires TyrNovo

UCB reports progress from genetics collaborations with leading universities

Addex Therapeutics presents promising in vitro and in vivo results for ADX-71441

Amgen publishes phase III data for etelcalcetide

Lifesci Pharmaceuticals patent reports kallikrein B inhibitors

Ono Pharmaceutical patents BRK inhibitors for cancer

Nanyang Technological University reports viral entry inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...